Retatrutide Side Effects: What the Trials Found, Dose by Dose

Disclosure: The RX Index earns money from some partner links. We do not link to retatrutide sellers, and no partner paid for a mention on this page. Links to partners are labeled where they appear.

This page is educational. It cannot diagnose a symptom or replace a clinician, Poison Control, or emergency care.

Retatrutide is not approved by the FDA. It cannot be legally sold or compounded for routine patient use. A small number of U.S. patients may be able to receive it only through an authorized clinical trial or a clinician-led FDA expanded-access request.

The verdict on retatrutide side effects

The most common retatrutide side effects are nausea, diarrhea, constipation, and vomiting. In the largest trial, at the top 12 mg dose, 42.4% of people had nausea, 32.0% had diarrhea, 26.1% had constipation, and 25.3% had vomiting. Retatrutide also has a notable altered-skin-sensation side effect called dysesthesia. At 12 mg, it ranged from 4.4% to 20.9% across five Phase 3 trials.

Three things change those numbers for you. Your dose. How fast you climbed to it. And where your medication came from.

That last one can change everything—and it is the part almost nobody writes about. We will get there.

Is this page for you?

Yes, if you:

• Are taking a product sold as retatrutide right now and want to know how your symptom compares with trial reports
• Want the real numbers by dose, not one blurry average
• Are trying to figure out whether a symptom needs a doctor
• Want to know what is still unknown

No, if you:

• Want a weight-loss comparison—see retatrutide vs. tirzepatide or retatrutide vs. semaglutide
• Want dosing instructions. We do not publish those, and you should not take them from a website
• Want to know where to buy it. We do not link to sellers

Stop reading and get help now if you have: trouble breathing; swelling in your face, lips, tongue, or throat; collapse; a seizure; severe stomach pain that will not quit; vomiting or diarrhea you cannot stay ahead of; a racing or irregular heartbeat that will not calm down; fainting; yellow skin or eyes; dark urine; or symptoms getting worse fast. Jump to the urgent-help section.

What we actually verified

We did not rewrite someone else's article. Here is exactly what we read:

• The published safety tables from the five retatrutide Phase 3 trials with public safety results as of August 8, 2026—TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRIUMPH-4, and TRANSCEND-T2D-1. Together, those trials enrolled 6,422 people.
• The full Phase 2 paper in the New England Journal of Medicine, including its adverse-event table and supplement.
• The FDA's current statement on unapproved GLP-1 drugs.
• A June 2026 preprint that analyzed Reddit posts from 13,589 users who reported current retatrutide use. Its percentages are not trial incidence rates.
• A government health alert from Victoria, Australia, about six acute liver-injury cases after use of unapproved products carrying the retatrutide name.
• The current FDA labels for Wegovy and Zepbound, because dysesthesia is no longer accurate to describe as unique to retatrutide.

What we did not do: test any product, sell retatrutide, invent a doctor to put in the byline, turn self-reported posts into medical incidence rates, or guess at numbers we could not find.

The RX Index is the independent GLP-1 decision resource that scores telehealth providers and treatment paths on clinical legitimacy, care quality, transparency, access, and cost, so readers can choose the path that fits their situation.

What are the side effects of retatrutide?

Retatrutide's most common side effects are stomach and gut problems: nausea, diarrhea, constipation, and vomiting. Dysesthesia—an unusual burning, tingling, prickling, or over-sensitive feeling in the skin—was also reported more often with retatrutide than with placebo. In the trials, most reported events were mild to moderate, and the rates usually climbed as the dose went up.

Here is one table that puts the public top-dose safety numbers from all five readout trials beside their placebo rates.

Retatrutide side effects at 12 mg across five Phase 3 trials

“P” is the placebo rate. “NR” means the company or paper did not report that number in the public table. NR does not mean zero.

One rule before you read this table: these trials enrolled different people, ran for different lengths of time, and were never designed to be compared against each other. A lower number in one row does not mean that trial was safer. It means the people, setting, follow-up, or reporting were different.

The gaps between trials are the real story

Look at what happened to the same 12 mg target dose across five studies:

That is the finding. “Retatrutide causes nausea in X% of people” is not a real answer. Nausea nearly doubled depending on which study you read. Dysesthesia varied by almost five times.

Anyone giving you one clean percentage is either using one trial and not telling you, or averaging numbers that should never be averaged.

Not all evidence here is equal—and we label it

Among the six studies used here, two have full peer-reviewed papers. Four TRIUMPH readouts are still company disclosures.

A press release from the company that makes the drug is real information. It is not the same thing as a full paper that outside scientists can inspect line by line. Most pages treat the two as identical. We will not.

Why retatrutide's side effects are not quite like other GLP-1 drugs

Semaglutide hits one target in your body. Tirzepatide hits two. Retatrutide hits three—GIP, GLP-1, and a third one called glucagon.

Glucagon can raise blood sugar, while glucagon-receptor activity may also raise energy use. That tension is why people worry about this drug.

Here is something that calms most people down: retatrutide is weaker at the glucagon target than your own body's glucagon. About 30% as strong, according to the researchers who published the Phase 2 trial. It is also weaker at the GLP-1 target than your own GLP-1—about 40%. Where it is strong is GIP, at nearly nine times.

So it is not a glucagon bomb. It is a tuned mix of three signals. We will come back to what the glucagon part actually did in the trials.

Retatrutide side effects by dose: 4 mg, 9 mg, and 12 mg

Side effects generally rose with dose, but not in a straight line and not for every symptom. In two separate trials, people on the lowest 4 mg dose actually quit because of side effects less often than people taking placebo. Starting dose and how many steps you climb can matter—not just where you end up.

Here is how every target dose was reached in the Phase 3 program. This is the trial protocol, not a dosing guide for personal use.

Every step was four weeks apart. Nobody in those Phase 3 arms jumped straight to a target dose.

Selected side effects by dose, side by side

Notice that last row. In TRANSCEND-T2D-1, 9 mg had less dysesthesia than 4 mg. Higher dose, fewer reported skin symptoms. Dose is not the whole story.

Correction: 60% was not the 12 mg nausea rate

You may see 60% cited as the 12 mg nausea number. It is misplaced, and we want to fix it here because the mistake changes how people understand this drug.

The Phase 2 trial had two groups that both ended at 8 mg—but one started at 2 mg and the other started at 4 mg.

The 60% belongs to the 8 mg group that started at 4 mg. It was never the 12 mg number. The 12 mg group reported 45%.

Now look at what that table actually shows you. Same target dose. The group that started one step lower reported nausea at 17% instead of 60%. Vomiting was 6% instead of 26%.

That is the single most useful fact on this page.

The honest counterpoint: in that same 8 mg comparison, the gentler-start group had a slightly higher adverse-event dropout rate—14% versus 6%. But that was five people versus two people. Too small to carry much weight. We are telling you anyway.

What this means if your medication did not come from a trial

Every published side-effect number for retatrutide was produced by people on a slow, supervised ladder. Four weeks at each step. A study team checking in. A verified dose in a verified study product.

The trial numbers are not a property of the molecule alone. They are a property of the molecule plus the schedule, product quality, screening, and follow-up. A vial from a website does not come with those guarantees.

The right path is not the same for everyone

The right GLP-1 provider is not the same for everyone—it depends on your state, your insurance and formulary, whether you want an FDA-approved drug or are considering a compounded product, which is not FDA approved, your preferred treatment path, and your budget. Because a general answer cannot resolve those for you, use The RX Index's Find My GLP-1 Path tool to get a personalized route with source-linked pricing before you choose.

One thing to be clear about: Find My GLP-1 Path never matches anyone to retatrutide or to a seller of unapproved products. There is no routine legal retail version of that match.

Which retatrutide side effects mean you should get medical help today?

Call emergency services now for trouble breathing, swelling of the face or throat, collapse, a seizure, someone who cannot be woken, or any symptom that seems life-threatening. Get urgent medical help for severe stomach pain that will not go away, vomiting or diarrhea you cannot keep up with, a racing or irregular heartbeat that does not settle when you rest, fainting or nearly fainting, yellow skin or eyes, dark urine, or unusual bruising. In the United States, Poison Control can be reached 24 hours a day at 1-800-222-1222 for a suspected reaction to an unknown or mislabeled product.

We put this section near the top on purpose. If you are in trouble right now, you should not have to dig through the rest of this page to find it.

Call 911 immediately for

• Trouble breathing
• Swelling in the face, lips, tongue, or throat
• Collapse or passing out
• A seizure
• Someone who cannot be woken up
• Any symptom that is severe and getting worse fast

Call Poison Control if you took something and do not know what it was

United States: 1-800-222-1222. Free, confidential, 24 hours a day. Poison specialists handle unknown-product exposures every day and they are not there to lecture you.

Australia: the Victorian Poisons Information Centre is 13 11 26, also 24/7.

This is not a small or theoretical problem. CBS News reported that retatrutide exposures reported to U.S. poison centers averaged 95 a month in the first four months of 2026—a 265% jump from the last four months of 2025. Reported problems included vomiting, fainting, rapid heart rate, and severe stomach distress. A poison-center report does not prove the product contained retatrutide, but that is exactly why the call matters.

If you are in a clinical trial, call your study team—unless it is an emergency

For a non-life-threatening problem, the study team knows your exact dose, schedule, product, and reporting rules. For an emergency, call emergency services first.

How to talk to a doctor if you bought it online

This is the part that stops people, and it is worth saying plainly: you are not the first person a doctor has seen after using a product sold as retatrutide. You do not need a perfect explanation before you ask for help.

Here is a sentence you can use, word for word:

“I've been using a product sold as retatrutide. I do not know for sure what was in it. I started around [date], I last took about [amount] on [date], and here is what I have been feeling.”

Then stop. That is enough to start helping you.

You can also report what happened to the FDA through its MedWatch program. Patients can file directly—you do not need a doctor to do it for you. Reports from ordinary people are how safety signals get found.

One more thing. Rachel Pessah-Pollack, MD, a clinical professor of medicine at NYU Langone Health, warned that people using retatrutide without needing that much weight loss could face serious muscle loss, gallstones from losing weight too fast, and nutrition problems. That is a clinician's warning, not a measured retatrutide rate, but it applies to many people using unapproved products without follow-up.

### Make a one-page note for the doctor Copy this into your phone before you call or go in:

• Product name printed on the package:
• Where it came from:
• Date first used:
• Date and amount last used:
• Symptoms and when each started:
• Other medicines, supplements, or peptides used:
• Photos of the vial, package, lot number, and mixing supplies:

Do not leave out another drug because you feel embarrassed. The combination may be the clue that changes what the doctor checks first.

What is dysesthesia, and does it go away?

Dysesthesia means an unpleasant or abnormal skin sensation—burning, tingling, prickling, or skin that feels sore or too sensitive to touch. At the top 12 mg retatrutide dose, it was reported by 4.4% to 20.9% of participants across five Phase 3 trials. Most events were mild to moderate, but the peer-reviewed TRANSCEND trial reported three severe cases and two treatment stops.

Dysesthesia is prominent in retatrutide data. It is not unique to retatrutide. The current Wegovy label reports dysesthesia in 6% of people taking 2.4 mg and 22% taking the newer 7.2 mg dose, versus 0.3% on placebo. The current Zepbound label lists it at 0.2% to 0.4%, versus 0.1% on placebo.

That 2026 label change matters. Any page saying semaglutide does not cause dysesthesia is now out of date.

Three words that mean slightly different things

Trials may group related skin-sensation terms together. If you have read three articles that used three different words, that is often why.

Every Phase 3 retatrutide dysesthesia rate published so far

Why you keep seeing “1 in 5”—and why it is one trial, not the whole answer

The 20.9% number is real. It is also the highest one, from the smallest of the five Phase 3 trials in this table—445 people with obesity and knee arthritis.

Line up all five trials at that same 12 mg target dose and the middle reported number is 7.3%.

That median is a description of five unlike studies. It is not a pooled risk estimate. The honest answer is that the reported 12 mg rate ranged from about 1 in 23 to 1 in 5, depending on the trial.

What the researchers said about it

The Phase 2 paper in the New England Journal of Medicine found that these skin sensations were mild to moderate, none were severe or serious, none came with a visible skin change, and none caused anyone to stop treatment.

The supplement gives the part most summaries leave out: of 20 altered-skin-sensation events, 16 had resolved, two were resolving, and two were still unresolved at the four-week follow-up after treatment ended. That does not prove permanence. It also does not support promising that every case clears quickly.

The same paper found that the skin symptoms did not appear connected to how much or how fast people lost weight.

TRANSCEND-T2D-1 added a harder edge: 15 people reported dysesthesia, three cases were severe, and two people stopped treatment because of it. The majority resolved while treatment continued.

What causes it? Nobody knows yet

You will find pages confidently telling you the glucagon target is responsible. There is no published evidence establishing that. It is a reasonable guess. It is still a guess.

We would rather tell you “we do not know” than make something up that sounds smart.

It had a different name in Phase 2

The 2023 Phase 2 trial called it “cutaneous hyperesthesia and skin sensitivity,” reported in 7% of people on retatrutide versus 1% on placebo. Phase 3 reports use the broader term dysesthesia.

These are related event groupings, not proof that every term means the exact same feeling in every person.

How to describe it clearly

Useful words include burning, prickling, tingling, painful touch, sunburn-like soreness, numbness, and clothing hurts the skin. Tell the clinician where it is, when it started, whether the skin looks normal, whether it is on one side or both, and whether you also have weakness, a rash, swelling, trouble walking, or facial symptoms.

That description helps. It does not tell you the cause by itself.

How long do retatrutide side effects last?

The trials did not publish one fixed number of days. Gut symptoms clustered around dose increases rather than spreading evenly across treatment. Most reported events were mild to moderate. Phase 2 heart-rate increases peaked around week 24 and eased afterward, while most dysesthesia events in the Phase 3 reports resolved during treatment.

The pattern: more step-up windows, more chances for symptoms

Here is the math nobody spells out. Every dose increase in the Phase 3 trials came four weeks after the last one. So:

• Getting to 4 mg meant one step-up window
• Getting to 9 mg meant three step-up windows over 12 weeks
• Getting to 12 mg meant four step-up windows over 16 weeks

The Phase 2 researchers found gut side effects happened mainly during this climbing phase.

That does not mean every person will feel sick at every step. It means a single answer such as “nausea lasts two weeks” is not supported by the retatrutide trials.

What we will not tell you

We are not going to say side effects “usually go away in two to four weeks.” No retatrutide trial published that as a personal timeline. Anyone who gives you a fixed number is guessing or borrowing it from a different drug.

What we can say from the published data: most events were mild to moderate, most people kept going, and many tracked symptoms resolved during treatment. Some did not resolve by the last follow-up available.

Your own timeline depends on the symptom, dose, pace of escalation, other medicines, health conditions, hydration, and—again—whether what you used was actually retatrutide.

Does retatrutide hurt your heart, blood sugar, or liver?

The three biggest fears come from retatrutide's glucagon component. So far, the trials have not shown a consistent high-blood-sugar or liver-injury signal from the study drug. Heart rate did rise in Phase 2, while the published Phase 3 diabetes trial showed much smaller average pulse changes at week 40. None of that settles long-term heart safety.

Blood sugar: the number that surprises people

TRIUMPH-3 studied people with severe obesity and existing heart disease. Hyperglycemia was reported as a side effect in 3.9% of the 9 mg group and 3.1% of the 12 mg group. On placebo, it was 13.4%.

In that trial, reported high blood sugar was about four times more common on placebo than at 12 mg.

The rest of the picture points the same way:

• In TRIUMPH-2, where every participant had type 2 diabetes, A1C fell by 1.4%, 1.6%, and 1.5% at 4, 9, and 12 mg. Placebo fell 0.2%.
• In Phase 2, 72% of participants who started with prediabetes returned to normal blood sugar. On placebo, 22% did.
• Phase 2 reported no clinically significant level 2 or level 3 low blood sugar.
• In TRANSCEND-T2D-1, level 2 low blood sugar occurred in 2% at 9 mg and 1% at 12 mg. No severe low-blood-sugar events occurred.

The glucagon fear is one of the most repeated worries about this drug. The trial data so far point the other way on average blood-sugar control. That does not make personal low or high blood sugar impossible.

Heart rate: real, but the size is not one clean number

Phase 2 found a dose-related heart-rate increase that peaked around week 24 and then declined. At week 48, the 12 mg group was still about 6 beats per minute above baseline, while placebo was about 0.4 bpm above baseline.

TRANSCEND-T2D-1 gives us the first peer-reviewed Phase 3 pulse data. At week 40, mean pulse changed by:

• -0.1 bpm at 4 mg
• +1.5 bpm at 9 mg
• +0.9 bpm at 12 mg
• -1.1 bpm on placebo

Those are different trials in different people. They should not be averaged. They show why “retatrutide raises heart rate by X” is too simple.

Phase 2 reported arrhythmia-related events in about 5.6% on retatrutide and 2.9% on placebo. Most were mild to moderate. One severe event deserves its own warning.

The ondansetron case—and what it does not prove

There was one severe prolonged-QT event in Phase 2. The participant had severe vomiting, was treated with ondansetron, and then had low potassium, dehydration, low blood pressure, and temporary liver injury. The problems resolved after treatment stopped.

That case does not prove a retatrutide-ondansetron drug interaction. It does show how fast severe vomiting, dehydration, electrolyte loss, and another medicine that can affect heart rhythm can become one medical problem.

You get badly nauseous. You get dehydrated. You take an anti-nausea medicine. And nobody is watching the whole picture.

If you are taking anything for nausea alongside a GLP-1—prescription or otherwise—that combination needs a clinician's eyes on it. This is one of the most concrete reasons to get a real doctor involved.

What Phase 3 still has not answered

TRANSCEND-T2D-1 published pulse data through 40 weeks. The public TRIUMPH-1, -2, -3, and -4 disclosures did not publish detailed heart-rate tables.

There is still no multi-year, approved-use heart-safety record. The existing numbers are useful. They are not the last word.

Retatrutide has no boxed warning—and that is not good news

Wegovy and Zepbound have FDA-reviewed labels with boxed warnings about thyroid C-cell tumors seen in rodents.

Retatrutide does not have a boxed warning.

That is not because the FDA found it safer. It is because retatrutide has no FDA label at all. A boxed warning is part of a reviewed label. Retatrutide has not completed that review.

For a plain-English breakdown of what label terms actually mean, see GLP-1 contraindication vs. warning vs. precaution.

Why do people online report completely different side effects?

Because the online percentages are not clinical-trial incidence rates, and the researchers could not verify the product, dose, source, schedule, other drugs, or medical history. The Reddit pattern is still striking: increased appetite, fatigue, increased energy, and insomnia appeared much more often in the posts than they did in retatrutide trial tables. That gap raises questions. It does not prove what was in any vial.

This is the part of the page we think matters most. Take your time with it.

There are two retatrutide side-effect lists—but they measure different things

In June 2026, researchers from the University of Pennsylvania and Boston Children's Hospital posted a medRxiv preprint. They analyzed 148,640 retatrutide-related posts and comments from online communities through December 2025.

Their model identified 13,589 unique Reddit users who reported current retatrutide use. After exclusions, 7,823 users with at least one retained mapped symptom became the denominator for the symptom percentages.

That last sentence matters. These are not percentages of all people who used retatrutide. They are shares of a selected group of symptom-reporting Reddit users.

The preprint says these figures cannot estimate incidence, causation, dose response, or comparative safety.

The number that stopped us cold

In Lilly's TRIUMPH-2 diabetes trial, 17.1% of people on the top 12 mg dose reported appetite going down.

In the Reddit analysis, 17.1% of the selected symptom-reporting users had a mapped term for appetite going up.

Same number. Opposite direction.

That is 1,336 out of 7,823 users.

But these are not mirror-image clinical rates. One came from structured trial reporting in a randomized treatment arm. The other came from posts by a selected online group, and the preprint excluded decreased-appetite terms from its symptom denominator.

The symmetry is memorable. The study design is what keeps it from being a verdict.

What the gap can—and cannot—mean

Read the gut rows again. The Reddit shares are much lower than the TRIUMPH-1 target-dose rates, while increased appetite, insomnia, and increased energy stand out in the posts.

Possible explanations include:

• A product that was underdosed, degraded, contaminated, mislabeled, or not retatrutide
• Mistakes while mixing or measuring a powder
• Using several peptides or drugs at the same time
• A community with many weightlifters and different goals than trial participants
• People with a bad or strange experience being more likely to post
• A symptom being blamed on retatrutide when something else caused it
• A true effect that formal trials have not yet captured

The study cannot tell us which explanation is right or how often any of them happens.

If a product sold as retatrutide is making you hungrier, doing nothing, or causing symptoms that do not fit the trial pattern, that is worth telling a doctor. It is also a reason to question the product—not proof of what is wrong with it.

Being fair to the study

We want you to trust this page, so here is everything that limits the evidence:

• It is a preprint. It has not been peer reviewed.
• The groups are not comparable. Trial participants were screened, supervised, and measured. The online group wrote posts.
• People having a bad time may post more than people who feel fine.
• The researchers could not verify product identity, purity, dose, route, treatment length, other drugs, or medical history.
• The analysis cannot estimate incidence, causation, dose response, or comparative safety.
• The language model can miss or misclassify symptoms, even though a manual check showed strong performance.
• One author reported a university research grant from Novo Nordisk and consulting fees from Currax Pharmaceuticals.

All of that is true. And the pattern in the posts is still different enough to deserve attention—not a diagnosis.

Six people in Victoria developed acute liver injuries

This is not forum data. This is a government health department.

On June 19, 2026, Victoria's Department of Health issued a public alert. Since January 2026, six people in Victoria had developed acute liver injury after using unapproved peptide products labeled Retatrutide, Reta, R-10, or R-20. The products had been bought online, through friends, or through social media.

The symptoms listed in the alert included tiredness, stomach pain, itchy skin, dark urine, yellow skin or eyes, and easy bruising.

The department said contamination may have contributed and the product contents were still under investigation. The alert did not prove that authentic retatrutide caused the injuries. It proved that six people had acute liver injury after using unapproved products carrying the name—and that a label is not proof of what is inside.

Now put that next to the actual study drug. In Phase 2, liver enzymes above three times normal appeared in 1% of participants, and average liver enzymes at week 48 were unchanged or lower than at the start. TRANSCEND-T2D-1 reported no suspected drug-induced liver injury.

The trial product and those unapproved products did not come with the same chain of custody, testing, or quality control. That is the clearest conclusion the evidence supports.

What the FDA says about products being sold

The FDA's position is direct: retatrutide cannot be used in compounding under federal law. It is not a component of an FDA-approved drug and has not been found safe and effective for any condition.

The FDA has warned companies that sold products labeled “for research purposes” or “not for human consumption” directly to consumers with dosing instructions. The agency says such products may contain the wrong ingredient, too little, too much, no active ingredient, or harmful ingredients.

Lilly's own language is just as direct: retatrutide cannot be legally sold or marketed for human use. The narrow expanded-access program described later is a clinician-led exception, not a retail market.

Here is what enforcement looked like in a Public Citizen investigation published June 16, 2026:

• 14 FDA warning letters to companies selling retatrutide since December 2024
• As of May 2026, 11 of those companies were still advertising retatrutide or other unapproved peptides
• Eight were still selling retatrutide
• At least 14 hospitalizations had been reported in the FDA adverse-event system as of June 2026

Those reports do not prove that authentic retatrutide caused every event or that every reported product contained it. They show the size of the unapproved market and the limits of warning letters alone.

CBS News separately identified more than 120 websites and more than 50 U.S. clinics selling or promoting retatrutide. After reporters contacted them, at least 21 clinics removed retatrutide from their sites or changed the wording to say they did not offer it.

We are not going to name or link to a seller. If you came here hoping for a “safe vendor” list, we do not have one—and neither does anyone else who has not independently tested the exact product in your hand.

### If cost or access is why you went this route, check the legal paths before buying another vial Prices, pills, pen options, and insurance routes changed sharply in 2026. The RX Index's Find My GLP-1 Path tool asks about your state, insurance, preferred format, and budget. Then it shows which legal treatment routes may fit, with source-linked pricing. See which legal options fit my situation → It takes about two minutes, and there is no signup. It will not route you to retatrutide or an unapproved seller.

How often did side effects make people stop taking retatrutide?

At the top 12 mg dose, the share of people who quit because of side effects ranged from 5.1% to 18.2% across the five Phase 3 trials. In two separate trials, the lowest 4 mg dose had a lower quit rate than placebo. And the scariest number in the program drops by a third in the BMI 35+ subgroup Lilly reported separately.

Three corrections to the 18.2% everyone quotes

One: it drops by a third in the BMI 35+ subgroup. Lilly reported that among TRIUMPH-4 participants who started with a BMI of 35 or higher, the quit rate was 12.1% at 12 mg, not 18.2%. The company said the rates were closely tied to starting BMI.

Two: some people quit because they believed they were losing too much weight. Lilly's release says the discontinuations included perceived excessive weight loss. In Phase 2, 13 people on retatrutide reached a BMI of 22 or lower, eight had their dose reduced by protocol, and nobody went below a BMI of 19.

Quitting a weight-loss drug because the loss feels excessive is a different event from quitting because nausea makes life miserable. Both can land in the same broad discontinuation category.

Three: the lowest dose beat placebo. Twice.

In TRIUMPH-1, people on 4 mg quit for side effects at 4.1%. Placebo was 4.9%. In TRIUMPH-2, 4 mg was 3.8% against 4.9% for placebo.

The two trials enrolled 3,491 people in total, and the same low-dose pattern appeared in both: the 4 mg arm had a lower observed adverse-event quit rate than placebo. That does not prove 4 mg prevents side effects. It does show why dose matters.

One oddity worth knowing

TRIUMPH-2's quit rate did not climb steadily. It went 3.8% at 4 mg, jumped to 11.6% at 9 mg, then fell to 7.7% at 12 mg.

The middle dose was harder to tolerate by this measure than the top dose. We do not have a public explanation, and we are not going to invent one.

Quitting is not the same as a serious event

“Stopped because of a side effect” and “had a serious adverse event” are different categories.

Someone can quit because nausea made life miserable. That is real and it matters. It is not the same as a hospitalization.

In Phase 2, serious adverse events happened in 4% of people on retatrutide and 4% of people on placebo. Identical.

Are retatrutide side effects worse than Zepbound or Wegovy?

No head-to-head safety trial has compared retatrutide with Zepbound or Wegovy, so nobody can honestly rank them from safest to most dangerous. The gut side effects overlap. Dysesthesia now appears on all three evidence records, but at very different rates. The clearest difference is that Zepbound and Wegovy have FDA-reviewed labels, while retatrutide does not.

Here is the part that does not help our case

We should be straight with you about something.

Retatrutide's top Phase 3 means—28.3% in TRIUMPH-1 and 28.7% in TRIUMPH-4—are higher than the main obesity-trial means reported for Wegovy and Zepbound. That is real.

We are not going to pretend otherwise to sell you something.

But the numbers do not come from one race. Retatrutide, tirzepatide, and semaglutide were studied in different people, for different lengths of time, with different rules. The raw gap is not a personal forecast.

And here is the thing that actually decides the safety question: retatrutide's trial numbers came from verified study drug, a known dose, a slow protocol, screening, and follow-up. A product from an unapproved seller is not that trial.

A smaller number you can trust beats a bigger number you cannot.

If your priority is squeezing out the absolute maximum possible loss and you are willing to accept unknown product quality to chase it, we are not the right resource for you—and honestly, no legitimate one is. If you would rather have a known drug, a known label, and someone accountable for your care, keep reading.

What can be compared fairly

For deeper comparisons, see retatrutide vs. tirzepatide and retatrutide vs. semaglutide.

What cannot be said

Do not let anyone tell you retatrutide is “three times more dangerous” because it hits three targets. Do not let anyone tell you it is safer because one trial showed a lower percentage than a different trial of a different drug. And do not let anyone say dysesthesia is unique to retatrutide now that the 2026 Wegovy label says otherwise.

None of those claims survives the current evidence.

Is retatrutide FDA approved, and can you get it legally?

No. Retatrutide is not FDA approved and there is no routine prescription or pharmacy route. Lilly says it has not been approved by any regulatory agency. In the United States, lawful patient access is limited to an authorized clinical trial or a clinician-led expanded-access request that Lilly, the FDA, and an ethics board authorize. Lilly plans to submit its U.S. application in the first quarter of 2027. No FDA decision date or launch date has been set.

The expanded-access program—and why almost nobody qualifies

For years there was no public early-access path. STAT reported in June 2026 that Lilly and the FDA had allowed one 79-year-old patient special access; the request had been made in April. After doctors asked why other patients could not seek the same path, Lilly confirmed on August 3, 2026 that it was reviewing expanded-access requests from clinicians.

Publicly reported requirements include:

1. Age 18 or older
2. Refractory obesity—a BMI of 35 or higher despite adhering to and tolerating the highest available dose of an approved chronic weight-management therapy
3. At least two serious or life-threatening obesity-related complications that are currently being treated
4. Unable to join an ongoing retatrutide trial or a comparable investigational trial

Medscape also reported that standard options, including bariatric surgery, are expected to have been discussed through shared decision-making.

You cannot apply by yourself. Your treating clinician has to request access, Lilly has to agree to provide the drug, and the FDA and an institutional review board must authorize the use.

The drug company is the first gate, not the FDA. Meeting the public criteria does not guarantee access.

A clinician considering this route should get the current requirements directly from Lilly rather than rely on a news summary.

Clinical trials

Trial openings change by site and can close without warning. As of August 8, 2026, Lilly's trial finder listed TRIUMPH-7 as enrolling. It is a Phase 3 study of retatrutide in 586 adults with obesity or overweight and chronic low back pain.

That is one example, not a promise of a nearby opening or eligibility. Use Lilly's live trial finder or The RX Index GLP-1 clinical-trials tracker and confirm the status with the study site.

What you can actually get today

Retatrutide is not one of the approved choices. Three current incretin options highlighted here are:

• Zepbound (tirzepatide)—weekly injection
• Wegovy (semaglutide)—weekly injection, including a higher-dose option, or a daily tablet
• Foundayo (orforglipron)—a daily pill, FDA approved April 1, 2026

Other approved weight-management medicines also exist. A clinician decides what is appropriate based on your health, medications, and label eligibility.

### Check insurance before assuming the approved path costs too much Ro's free GLP-1 Insurance Coverage Checker currently checks plan coverage for the Ozempic pen, Wegovy pen, and Zepbound pen. It does not currently check Foundayo, the Wegovy pill, or Zepbound KwikPen coverage. Ro Body is listed at $39 for the first month, then as low as $74 a month with an annual plan paid up front, or $149 a month on the monthly plan. Medication is separate. Check my coverage free → (partner link; provider-stated terms verified August 8, 2026) A coverage check does not submit a prescription or obligate you to join.

### Paying cash and want to choose a clinician? Sesame's current program page lists starting cash-pay medication prices of $149 a month for Foundayo, $149 a month for the Wegovy pill, and $299 a month for Zepbound KwikPen. Dose, eligibility, supply, and the separate care-program fee can change the total. See current Sesame options → (partner link; provider-stated terms verified August 8, 2026)

Neither option is retatrutide. Nobody has an FDA-approved retail retatrutide product, including our partners.

For a broader decision page, see five legal retatrutide alternatives you can actually get.

What do we still not know about retatrutide?

A great deal. The longest public retatrutide result runs 104 weeks in a selected extension group of 532 people, and that result is still a company disclosure rather than a full peer-reviewed paper. There is nothing at three years, five years, or ten years. Retatrutide has no approved label listing final contraindications, required monitoring, drug interactions, or post-market safety findings.

To keep this honest, we sort everything into three buckets. Most pages blur them together, which is how a warning from a different drug ends up presented as a retatrutide fact.

Bucket 1: What retatrutide trials actually observed

Nausea, diarrhea, constipation, vomiting, decreased appetite, dysesthesia, urinary tract infections, upper respiratory infections, dose-related heart-rate changes, low blood sugar in a small share of the diabetes trial, and the discontinuation rates above.

One case of acute pancreatitis occurred in the 12 mg Phase 2 arm while the participant was still at a 2 mg current dose early in escalation. One case cannot establish how often something happens or prove the drug caused it. TRANSCEND-T2D-1 reported no adjudicated pancreatitis.

Phase 2 reported no medullary thyroid cancer and no C-cell changes. TRANSCEND-T2D-1 also reported no medullary thyroid cancer.

And here is a finding almost nobody publishes: in the Phase 2 trial, the only reported major-depression or suicidal-thinking event occurred in the placebo group. Zero were reported across the retatrutide arms. That does not prove protection or rule out a rare risk; the trial was small and selected.

One death occurred in Phase 2—a drowning judged unrelated by the site investigator. TRANSCEND-T2D-1 reported two deaths in the 4 mg group, both judged unrelated to study treatment.

Bucket 2: Concerns borrowed from approved drugs—not established retatrutide label warnings

Approved GLP-1 and GIP/GLP-1 labels warn about issues that can include pancreatitis, gallbladder problems, kidney injury linked to dehydration, low blood sugar with certain diabetes medicines, diabetic-eye complications, heart-rate increases, and food entering the lungs during anesthesia or deep sedation.

Those are warnings from approved medicines in a related family. They are not retatrutide label warnings, because retatrutide has no label. They are useful context. They are not proof that every warning will appear in a future retatrutide label at the same rate or in the same form.

Bucket 3: Genuinely unknown

• Final contraindications—who should never take it
• Final warnings and precautions
• How often rare side effects happen
• Long-term safety over years
• Pregnancy and breastfeeding guidance
• Drug-interaction guidance
• Safety in people excluded from the trials
• What happens after treatment stops
• Whether it reduces, raises, or does not change major cardiovascular-event risk

That last one deserves a note. TRIUMPH-3 reported a hazard ratio of 0.82 (95% CI, 0.55–1.22) for its broader heart-event measure and 1.12 (95% CI, 0.64–1.96) for the narrower measure. Both confidence intervals crossed 1.0, and event counts were lower than expected. The trial could not tell whether retatrutide helps the heart, hurts it, or does neither. Anyone claiming proven heart protection is going beyond the data.

What is still missing on body composition

There is no published Phase 3 body-composition paper for retatrutide. The published body-composition evidence comes from a smaller Phase 2 substudy in people with type 2 diabetes.

If lean mass is your concern—and for many people it is—see our primary-source comparison of GLP-1 lean-mass findings by drug.

How we checked all of this

We built this page from primary sources first: FDA pages and labels, Eli Lilly's trial disclosures, the peer-reviewed Phase 2 and TRANSCEND-T2D-1 papers, a government health alert from Australia, and the full university preprint on Reddit reports. We recorded each trial's population, dose, placebo rate, duration, and evidence stage. We did not average unlike studies or treat them as head-to-head comparisons.

Our source order

1. FDA and other government regulators
2. Peer-reviewed trial publications and supplements
3. ClinicalTrials.gov and sponsor trial records
4. Company trial disclosures—clearly labeled as such
5. Approved drug labels, for family context only
6. Established news outlets for access and enforcement developments
7. Online posts, for signals and language only—never as medical incidence data

What we deliberately did not do

• Average different trials into one risk number
• Treat “not reported” as “zero”
• Compare percentages across trials as if they were head to head
• Turn Reddit symptom shares into incidence rates
• Diagnose anyone
• Publish personal dosing, titration, or mixing instructions
• Assume an online vial contains what the label says
• Invent a biological explanation for dysesthesia
• Make up a testimonial or a medical reviewer
• Publish a tool that does not exist

Still unverified or incomplete

Being honest about the edges:

• Four TRIUMPH studies here are still company disclosures, not full peer-reviewed papers
• Only TRANSCEND-T2D-1 has published detailed Phase 3 pulse data
• The Reddit analysis is a preprint and cannot verify products or users
• The Australian liver cases were still under investigation, and product contents had not been identified
• Public descriptions of the expanded-access criteria differ slightly
• Nobody can verify the contents of an individual reader's vial from a web page

Change log

We review this page monthly and sooner if a new safety alert, peer-reviewed publication, trial readout, or FDA decision lands.

Retatrutide side effects FAQ

What is the most common side effect of retatrutide?

Nausea was the most common in several trials, though diarrhea was higher in TRIUMPH-2 at 12 mg: 33.6% for diarrhea versus 28.0% for nausea. At the top 12 mg dose across the five Phase 3 trials, nausea ranged from 22.4% to 43.2%.

Does retatrutide cause hair loss?

Hair loss does not appear in the most-common adverse-event tables released for the retatrutide trials. In the Reddit preprint, alopecia was mapped for 0.6% of the 7,823 selected symptom-reporting users. That is not an incidence rate. Current Wegovy and Zepbound labels do list hair loss; the Zepbound label says those reports were associated with weight reduction.

Why am I hungrier on a product sold as retatrutide?

Increased appetite is not a recognized common retatrutide trial effect. The Reddit preprint mapped increased appetite for 17.1% of its selected symptom-reporting users, but it could not verify product identity, dose, source, or cause. Mention the change to a clinician and bring the package or a photo. It is a reason to question the product, not proof of what is inside.

Does retatrutide cause insomnia?

Insomnia was mapped for 6.1% of the selected Reddit users in the preprint. It does not appear in the common adverse-event lists released from the retatrutide trials. The study cannot tell whether retatrutide, another product, another drug, reporting bias, or something else caused the difference.

Does retatrutide raise your heart rate?

It did in Phase 2, with a dose-related rise that peaked around week 24 and eased afterward. At week 48, the 12 mg group remained about 6 bpm above baseline. In TRANSCEND-T2D-1, mean week-40 pulse changes ranged from -0.1 to +1.5 bpm across doses, versus -1.1 bpm on placebo. Long-term meaning is still unknown.

How long does nausea last on retatrutide?

The trials found gut symptoms clustered around dose increases. They did not publish a fixed personal timeline. A website that promises an exact number of days is guessing.

Is dysesthesia permanent?

The evidence cannot promise that it always clears. In Phase 2, 16 of 20 altered-skin-sensation events had resolved, two were resolving, and two were unresolved at the four-week follow-up. In TRANSCEND-T2D-1, most resolved during treatment, but three cases were severe and two people stopped treatment. The current Wegovy label also says some dysesthesia cases did not report recovery during the trial.

Can I take anti-nausea medicine with retatrutide?

That is a clinician question, not a website instruction. One severe prolonged-QT event in Phase 2 occurred in a participant with severe vomiting who was treated with ondansetron and then developed low potassium, dehydration, low blood pressure, and temporary liver injury. The case does not prove a specific drug interaction. It does show why severe vomiting and added medicines need real oversight.

Is retatrutide safe?

Nobody can give a final yes-or-no answer yet. Retatrutide has not completed FDA review, has no approved label, and has no long-term approved-use record. The trials show a side-effect pattern dominated by gut symptoms, with dysesthesia and heart-rate changes that need more study. A product from an unapproved seller adds a separate quality and identity risk that the trials cannot measure.

Can a compounding pharmacy legally make retatrutide?

No. The FDA says retatrutide cannot be used in compounding under federal law. It is not a component of an approved drug and has not been found safe and effective for any condition.

What should I do if I have been using retatrutide and want to stop?

Talk to a clinician before changing a treatment plan, especially if you have symptoms, use diabetes medicine, or take other drugs or peptides. Call emergency services for life-threatening symptoms and Poison Control at 1-800-222-1222 in the United States for a suspected exposure to an unknown product.

How do I report a side effect?

Use the FDA's MedWatch program. Patients can report directly. If you are in a trial, tell your study team too. For an urgent reaction to an unknown product, call Poison Control first.

Still not sure which GLP-1 program is right for you?

Take our free matching quiz.

The RX Index's Find My GLP-1 Path tool compares legal treatment routes based on your state, insurance, preferred format, and budget. You get a personalized route with source-linked pricing.

Start Find My Path →

It takes about two minutes, there is no signup, and it will not match you to retatrutide or to a seller of unapproved products.

Sources

Trial data

• Eli Lilly, TRIUMPH-1 topline results, May 21, 2026
• Eli Lilly, detailed TRIUMPH-1 and TRANSCEND-T2D-1 results, June 6, 2026
• Eli Lilly, TRIUMPH-2 and TRIUMPH-3 topline results, July 23, 2026
• Eli Lilly, TRIUMPH-4 topline results, December 11, 2025
• Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity—A Phase 2 Trial. New England Journal of Medicine. 2023
• Phase 2 trial supplementary appendix
• Bajaj HS, et al. TRANSCEND-T2D-1. The Lancet. Published online June 6, 202600967-0)

Regulatory, labels, and safety

• FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss
• FDA, Wegovy prescribing information, 2026
• FDA, Zepbound prescribing information, 2026
• FDA, Foundayo approval package, April 1, 2026
• Victorian Department of Health, Toxicity linked to unapproved peptide product labelled Retatrutide, June 19, 2026
• FDA MedWatch adverse-event reporting program
• America's Poison Centers

Online-report analysis

• Sehgal NKR, Tronieri JS, Rader B, Ungar L, Guntuku SC. Self-Reported Side Effects Among Reddit Users Taking Unapproved Retatrutide. medRxiv preprint, June 3, 2026

Enforcement, access, and clinician commentary

• Public Citizen investigation, June 16, 2026
• CBS News investigation of unapproved retatrutide sales and poison-center reports, June 2026
• STAT, report on the first 79-year-old expanded-access patient, June 23, 2026
• STAT, Lilly confirms broader expanded-access requests, August 3, 2026
• Medscape, published retatrutide expanded-access criteria, August 2026
• Reuters, Lilly expanded-access announcement, August 3, 2026
• Lilly expanded-access policy
• Lilly TRIUMPH-7 trial listing
• NYU Langone summary of clinician concerns, June 26, 2026

Provider terms checked August 8, 2026

• Ro Body membership pricing
• Ro GLP-1 Insurance Coverage Checker
• Sesame online weight-loss program and cash-pay medication prices